Neurodevelopment and the Origins of Brain Disorders

Neuropsychopharmacology

Volumn 40, Issue 1, 2015, Pages 1-3

  Levitt, Pat ^a   Veenstra VanderWeele, Jeremy ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPEPTIDE; OXYTOCIN; VASOPRESSIN;

AGGRESSION; ANTISOCIAL BEHAVIOR; AUTISM; BEHAVIOR DISORDER; BRAIN CORTEX; BRAIN DEVELOPMENT; BRAIN DISEASE; BRAIN FUNCTION; BRAIN MATURATION; BRAIN REGION; EDITORIAL; GENE MUTATION; GENETIC RISK; HUMAN; MATERNAL BEHAVIOR; MONOAMINERGIC SYSTEM; MULTIGENE FAMILY; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NEUROBIOLOGY; NEUROIMAGING; NONHUMAN; PERSONAL EXPERIENCE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA; SENSORY SYSTEM; SOCIAL COGNITION; SOCIAL DISABILITY; SYNAPSE; BRAIN DISEASES; CHILD DEVELOPMENT; DEVELOPMENTAL DISABILITIES; GENETIC EPIGENESIS; GENETICS; PHYSIOLOGY; PRESCHOOL CHILD;

BRAIN DISEASES; CHILD DEVELOPMENT; CHILD, PRESCHOOL; DEVELOPMENTAL DISABILITIES; EPIGENESIS, GENETIC; HUMANS;

EID: 84926682754     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.237     Document Type: Editorial

References (15)

1. Washbourne P (2015). Synapse assembly and neurodevelopmental disorders. Neuropsychopharmacology 40: 4-15.
2. Chu J, Anderson SA (2015). Development of cortical interneurons. Neuropsychopharmacology 40: 16-23.
3. Hammock EAD (2015). Developmental perspectives on oxytocin and vasopressin. Neuropsychopharmacology 40: 24-42.
4. Giedd JN, Raznahan A, Alexander-Bloch A, Schmitt E, Gogtay N, Rapoport JL (2015). Child psychiatry branch of the national institute of mental health longitudinal structural magnetic resonance imaging study of human brain developm ent. Neuropsychopharmacology 40: 43-49.
5. Hartley CA, Lee FS (2015). Sensitive periods in affective development: Nonlinear maturation of fear learning. Neuropsychopharmacology 40: 50-60.
6. Ross EJ, Graham DL, Money KM, Stanwood GD (2015). Developmental consequences of fetal exposure to drugs: What we know and what we still must learn. Neuropsychopharmacology 40: 61-87.
7. Suri D, Teixeira CM, Cagliostro MKC, Mahadevia D, Ansorge MS (2015). Monoamine-sensitive developmental periods impacting adult emotional and cognitive behaviors. Neuropsychopharmacology 40: 88-112.
8. Schoenfeld TJ, Camer on HA (2015). Adult neurogenesis and mental illness. Neuropsychopharmacology 40: 113-128.
9. Toth M (2015). Mechanisms of non-genetic inheritance and psychiatric disorders. Neuropsychopharmacology 40: 129-140.
10. Kundakovic M, Champagne FA (2015). Early life experience, epigenetics, and the developing brain. Neuropsychopharmacology 40: 141-153.
11. Humphreys KL, Zeanah CH (2015). Deviations from the expectable environment in early childhood and emerging psychopathology. Neuropsychopharmacology 40: 154-170.
12. Hernandez LM, Rudie JD, Green SA, Bookheimer S, Dapretto M (2015). Neural signatures of autism spectrum disorders: Insights into brain network dynamics. Neuropsychopharmacology 40: 171-189.
13. Schmidt MJ, Mirnics K (2015). Neurodevelopment, GABA system dysfunction, and schizophrenia. Neuropsychopharmacology 40: 190-206.
14. Henderson HA, Pine DS, Fox NA (2015). Behavioral Inhibition and developmental risk: A dual-processing perspective. Neuropsychopharmacology 40: 207-224.
15. Veenstra-VanderWeele J, Warren Z (2015). Intervention in the context of development: Pathways toward new treatments. Neuropsychopharmacology 40: 225-237.